» Authors » James E Korkola

James E Korkola

Explore the profile of James E Korkola including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 58
Citations 2340
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Garay J, Smith R, Devlin K, Hollern D, Liby T, Liu M, et al.
Breast Cancer Res . 2021 Aug; 23(1):81. PMID: 34344439
Background: HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these targeted therapies is a common problem, but...
12.
Smith R, Liu M, Liby T, Bayani N, Bucher E, Chiotti K, et al.
Sci Rep . 2020 Dec; 10(1):21750. PMID: 33303959
Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our treatment of prostate cancer. Here we describe...
13.
Ou H, Hoffmann R, Gonzalez-Lopez C, Doherty G, Korkola J, Munoz-Espin D
Mol Oncol . 2020 Sep; 15(10):2634-2671. PMID: 32981205
Senescence refers to a cellular state featuring a stable cell-cycle arrest triggered in response to stress. This response also involves other distinct morphological and intracellular changes including alterations in gene...
14.
Kersch C, Claunch C, Ambady P, Bucher E, Schwartz D, Barajas Jr R, et al.
Neurooncol Adv . 2020 Sep; 2(1):vdaa093. PMID: 32904984
Background: Glioblastoma is a rapidly fatal brain cancer that exhibits extensive intra- and intertumoral heterogeneity. Improving survival will require the development of personalized treatment strategies that can stratify tumors into...
15.
Bucher E, Claunch C, Hee D, Smith R, Devlin K, Thompson W, et al.
BMC Bioinformatics . 2019 Nov; 20(1):542. PMID: 31675914
Background: In biological experiments, comprehensive experimental metadata tracking - which comprises experiment, reagent, and protocol annotation with controlled vocabulary from established ontologies - remains a challenge, especially when the experiment...
16.
Niepel M, Hafner M, Mills C, Subramanian K, Williams E, Chung M, et al.
Cell Syst . 2019 Jul; 9(1):35-48.e5. PMID: 31302153
Evidence that some high-impact biomedical results cannot be repeated has stimulated interest in practices that generate findable, accessible, interoperable, and reusable (FAIR) data. Multiple papers have identified specific examples of...
17.
Smith R, Devlin K, Kilburn D, Gross S, Sudar D, Bucher E, et al.
J Vis Exp . 2019 Jun; (147). PMID: 31180341
Understanding the impact of the microenvironment on the phenotype of cells is a difficult problem due to the complex mixture of both soluble growth factors and matrix-associated proteins in the...
18.
Coleman D, Gao L, Schwartzman J, Korkola J, Sampson D, Derrick D, et al.
Sci Rep . 2019 Mar; 9(1):3823. PMID: 30846826
The BET bromodomain protein BRD4 is a chromatin reader that regulates transcription, including in cancer. In prostate cancer, specifically, the anti-tumor activity of BET bromodomain inhibition has been principally linked...
19.
Langer E, Allen-Petersen B, King S, Kendsersky N, Turnidge M, Kuziel G, et al.
Cell Rep . 2019 Jan; 26(3):608-623.e6. PMID: 30650355
The tumor microenvironment plays a critical role in tumor growth, progression, and therapeutic resistance, but interrogating the role of specific tumor-stromal interactions on tumorigenic phenotypes is challenging within in vivo...
20.
Donnella H, Webber J, Levin R, Camarda R, Momcilovic O, Bayani N, et al.
Nat Chem Biol . 2018 Jun; 14(8):768-777. PMID: 29942081
Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly because of dynamic changes in...